Allergan Plc (AGN) 317.00 $AGN
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 4.11 (+0.01), FOMX: 11.47 (+0.21), GSK: 42.63 (-0.39), PRTK: 26.64 (+0.78), AGN: 317.00 (-0.75), PVCT: 0.46 (unch), DERM: 23.05 (+0.47)
Technical Roundup on Drugs - Generic Equities -- Allergan, Akorn, Ironwood Pharma, Pacira Pharma, and Catalent
PR Newswire - Tue Jul 21, 8:15AM CDT
Equity Research Institute has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Catalent Inc. (NYSE: CTLT). Free research report on Allergan can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AGN On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
AGN: 317.00 (-0.75), IRWD: 11.29 (+0.11), AKRX: 44.75 (-0.17), CTLT: 29.45 (+0.04), PCRX: 62.89 (-0.55)
Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors
Business Wire - Tue Jul 21, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for ocular diseases, today announced that Richard N. Spivey, PharmD, PhD, has been appointed to its Board of Directors.
AGN: 317.00 (-0.75), ITEK: 5.06 (-0.12)
Allergan Launches Bold Campaign For Millennial Women
PR Newswire - Tue Jul 21, 6:00AM CDT
Allergan today launched #ActuallySheCanSM, an innovative campaign that inspires young millennial women to achieve their professional, personal, health, wellness and societal goals.
AGN: 317.00 (-0.75)
Tekmira suspends work on Ebola drug, will change name
AP - Mon Jul 20, 3:21PM CDT
NEW YORK (AP) — One of the companies that had been studying a potential treatment for the Ebola virus said Monday it will suspend its research on Ebola drugs and change its name.
AGN: 317.00 (-0.75), INO: 7.31 (-0.19), TKMR: 10.83 (-0.35), GSK: 42.63 (-0.39), TKM.TO: 22.97 (+0.52)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 317.00 (-0.75), AMBA: 118.18 (+0.46), NFLX: 112.51 (+1.96), BIIB: 409.50 (+0.57), GPRO: 62.04 (+1.24), AMZN: 488.00 (-0.10), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), FB: 98.39 (+0.48), GOOGL: 695.35 (+2.51), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01), MS: 40.08 (+0.04)
Allergan to Highlight Data from Its Alzheimer's Disease Portfolio at the 2015 Alzheimer's Association International Conference (AAIC)
PR Newswire - Mon Jul 20, 8:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that five poster presentations will be given at the 2015 Alzheimer's Association International Conference in Washington DC, July 17 through July 23. Highlights include analyses on the use of memantine, extended-release memantine, and combination therapy with memantine and donepezil. The following data will be presented at this year's meeting:
AGN: 317.00 (-0.75)
Allergan May Be Recovering From Faded Rally
at The Street - Mon Jul 20, 7:00AM CDT
It's settling into an attractive pattern.
AGN: 317.00 (-0.75)
AstraZeneca Strikes Deal to Market Benralizumab in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:50PM CDT
AstraZeneca (AZN) inked a deal with Kyowa Hakko Kirin for the commercialization of benralizumab for asthma and chronic obstructive pulmonary disease in Japan.
AGN: 317.00 (-0.75), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), AMAG: 72.59 (-1.83)
SAPHRIS® (asenapine) 2.5 mg Sublingual Tablets for the Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder in Pediatric Patients (ages 10-17) Now Available in Pharmacies throughout the U.S.
PR Newswire - Fri Jul 17, 7:00AM CDT
Allergan plc today announced that SAPHRIS® (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration (FDA) approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 - 17).
AGN: 317.00 (-0.75)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 123.98 (+1.04), AGN: 317.00 (-0.75), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), UTHR: 175.17 (-2.34), RCPT: 228.98 (+0.26), MOH: 72.56 (-0.42), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01)
Allergan Faces Patent Challenge for Eye Treatment Restasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 1:35PM CDT
Allergan (AGN) is facing a patent challenge from Akorn for Restasis.
AGN: 317.00 (-0.75), EBIO: 2.95 (-0.04), MYL: 67.21 (+0.23), RDY: 60.75 (-1.31)
5 Big Stocks to Trade for Earnings Season Gains
at The Street - Thu Jul 16, 11:32AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street right now.
HRS: 81.29 (-0.26), BSX: 17.76 (-0.12), AGN: 317.00 (-0.75), HD: 113.86 (+0.45), HRL: 57.46 (-0.40)
The Antiepileptic Drug Topiramate Dominates First Line Prophylactic Treatment of Migraine, with Allergan's Botox Exhibiting Growth in Later Lines
PR Newswire - Thu Jul 16, 8:30AM CDT
Decision Resources Group finds that, through analysis of U.S. longitudinal patient-level claims data, the antiepileptic drug (AED) topiramate (Ortho-McNeil/Janssen-Cilag's Topamax; other brands; generics) captured the greatest patient share among prophylactic treatment-naive migraine patients across the first three lines of therapy. Furthermore, topiramate patient shares among migraine patients recently treated with prophylactic therapies remained relatively constant over the previous year of analysis. These findings highlight topiramate's position as a first-line standard of care for migraine prevention. Overall, AEDs were the preferred drug class for migraine prophylaxis, with nearly half of prophylactically naive patients initiating prophylactic therapy with an AED.
AGN: 317.00 (-0.75)
Top World Stocks In Bases Or Buy Range As Greece Votes
at Investor's Business Daily - Wed Jul 15, 4:50PM CDT
It's a good idea to scan through the charts of IBD's Top World Stocks. What you find right now is three of those stocks in bases and another two in buying range just above buy points. A resolution to the eurozone's crisis with Greece could quickly...
AGN: 317.00 (-0.75), MNK: 123.98 (+1.04), NTES: 151.05 (+0.88), SHPG: 255.23 (-2.57), ABBV: 70.54 (-0.26), FLTX: 49.64 (-0.24), ICLR: 68.17 (-0.70)
Allergan Notes Receipt of Paragraph IV Notification on Restasis
PR Newswire - Wed Jul 15, 3:01PM CDT
Allergan plc (NYSE: AGN) today confirmed that the Company has received a notice letter dated July 10, 2015 (the "Notice Letter"
from Akorn Pharmaceuticals stating that the U.S. Food and Drug Administration (FDA) has received Akorn's Abbreviated New Drug Application (ANDA) containing a "Paragraph IV" patent certification seeking approval to market a generic version of Allergan's Restasis® (cyclosporine ophthalmic emulsion) 0.05% product. In addition, Allergan has received communication suggesting that additional ANDAs for generic versions of Restasis® may have been received by the FDA.
AGN: 317.00 (-0.75)
Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020
M2 - Wed Jul 15, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggwsk/global) has announced the addition of the "Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020" report to their offering. Alzheimer's disease is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer's disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. Global Alzheimer's Disease Drugs Market and Pipeline Drugs Analysis: In 2014, the global market for Alzheimer's disease drugs was dominated by Namenda and Exelon. Aricept and Memary stands at the third and fourth spot respectively in terms of Alzheimer's disease drugs sales in 2014. Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer's disease market. With the patent expiration of popular drugs the sales of the Alzheimer's drugs has also declined. However, there are several pipeline drugs like Solanezumab, Gantenerumab, Crenezumab and Lu AE58054 among others which are likely to hit the market during the period 2017 - 2020. Global Alzheimer's Disease Country Wise Analysis: In the Alzheimer's disease drugs market, the United States is the largest market. Japan is the second leading market for Alzheimer's disease drugs market in 2014. China stands at the third spot in the global Alzheimer's disease drugs market being followed by India. This report titled Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020 is a 150 page report with 74 Figures and 10 Tables. This report analyses the Alzheimer's Disease Drugs Market, Alzheimer's Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer's Disease - Country Wise Drugs Market, Country Wise Alzheimer's Disease Prevalence, Major Deals in Alzheimer's Disease Drugs Market Landscape, Funding in Alzheimer's Disease Drugs Research, Driving Factors and Challenges for Alzheimer's Disease Drugs Market. The Alzheimer's Disease Drugs Market has been analyzed from 7 View Points: 1. Alzheimer's Disease - Drugs Sales and Forecast 2. Alzheimer's Disease - Pipeline Drugs Sales Forecast 3. Alzheimer's Disease Drugs - Country Wise Market and Forecast 4. Alzheimer's Disease - Country Wise Prevalence and Forecast 5. Alzheimer's Disease - Pipeline Drugs Clinical Trials Analysis 6. Alzheimer's Disease - Major Deals in Alzheimer's Drugs Market 7. Alzheimer's Disease - Funding in Alzheimer's Disease Research The Top 9 Alzheimer's Disease Drugs covered in the report are as follows: 1. Exelon 2. Razadyne/Reminyl 3. Memary 4. Ebixa 5. Aricept 6. Rivastach 7. Namenda 8. Nootropil 9. Namzaric The 7 Pipeline Alzheimer's Disease Drugs covered in the report are as follows: 1. Solanezumab 2. ABT-126 3. idalopirdine 4. Gantenerumab 5. Crenezumab 6. Lu AE58054 7. BIIB037 The 9 Countries Alzheimer's Disease Drugs Market covered in the report are as follows: 1. United States 2. France 3. Germany 4. Italy 5. Spain 6. United Kingdom 7. Japan 8. China 9. India The Alzheimer's Disease Drugs Major Deals covered in the report are as follows: 1. Strategic Alliance 2. Licensing Agreement 3. Collaboration Deals 4. Mergers and Acquisitions Companies Mentioned - AbbVie - Allergan - Biogen - Daiichi Sankyo - Eisai - Lilly - Lundbeck - Novartis - Ono - Otsuka - Roche - Takeda For more information visit http://www.researchandmarkets.com/research/pggwsk/global
AGN: 317.00 (-0.75), NVS: 103.71 (-2.41)
'Mad Money' Lightning Round: I Still Believe in Harman International
at The Street - Wed Jul 15, 5:00AM CDT
Cramer thinks Walgreens, CVS and Rite Aid are great, prefers Allergan over Valeant and wants AT&T for growth and income.
AGN: 317.00 (-0.75), T: 34.57 (-0.33), VRX: 240.59 (+0.71), LC: 15.01 (+0.39), HAR: 109.25 (+3.21), WBA: 95.66 (+0.01), MPC: 57.15 (-0.38), CVS: 110.06 (-0.92), PYPLV: 38.39 (-0.24), RAD: 8.69 (-0.13)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 4.11 (+0.01), FOMX: 11.47 (+0.21), GSK: 42.63 (-0.39), PRTK: 26.64 (+0.78), AGN: 317.00 (-0.75), PVCT: 0.46 (unch), DERM: 23.05 (+0.47)
Technical Roundup on Drugs - Generic Equities -- Allergan, Akorn, Ironwood Pharma, Pacira Pharma, and Catalent
PR Newswire - Tue Jul 21, 8:15AM CDT
Equity Research Institute has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Catalent Inc. (NYSE: CTLT). Free research report on Allergan can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AGN On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
AGN: 317.00 (-0.75), IRWD: 11.29 (+0.11), AKRX: 44.75 (-0.17), CTLT: 29.45 (+0.04), PCRX: 62.89 (-0.55)
Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors
Business Wire - Tue Jul 21, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for ocular diseases, today announced that Richard N. Spivey, PharmD, PhD, has been appointed to its Board of Directors.
AGN: 317.00 (-0.75), ITEK: 5.06 (-0.12)
Allergan Launches Bold Campaign For Millennial Women
PR Newswire - Tue Jul 21, 6:00AM CDT
Allergan today launched #ActuallySheCanSM, an innovative campaign that inspires young millennial women to achieve their professional, personal, health, wellness and societal goals.
AGN: 317.00 (-0.75)
Tekmira suspends work on Ebola drug, will change name
AP - Mon Jul 20, 3:21PM CDT
NEW YORK (AP) — One of the companies that had been studying a potential treatment for the Ebola virus said Monday it will suspend its research on Ebola drugs and change its name.
AGN: 317.00 (-0.75), INO: 7.31 (-0.19), TKMR: 10.83 (-0.35), GSK: 42.63 (-0.39), TKM.TO: 22.97 (+0.52)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 317.00 (-0.75), AMBA: 118.18 (+0.46), NFLX: 112.51 (+1.96), BIIB: 409.50 (+0.57), GPRO: 62.04 (+1.24), AMZN: 488.00 (-0.10), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), FB: 98.39 (+0.48), GOOGL: 695.35 (+2.51), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01), MS: 40.08 (+0.04)
Allergan to Highlight Data from Its Alzheimer's Disease Portfolio at the 2015 Alzheimer's Association International Conference (AAIC)
PR Newswire - Mon Jul 20, 8:00AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that five poster presentations will be given at the 2015 Alzheimer's Association International Conference in Washington DC, July 17 through July 23. Highlights include analyses on the use of memantine, extended-release memantine, and combination therapy with memantine and donepezil. The following data will be presented at this year's meeting:
AGN: 317.00 (-0.75)
Allergan May Be Recovering From Faded Rally
at The Street - Mon Jul 20, 7:00AM CDT
It's settling into an attractive pattern.
AGN: 317.00 (-0.75)
AstraZeneca Strikes Deal to Market Benralizumab in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 3:50PM CDT
AstraZeneca (AZN) inked a deal with Kyowa Hakko Kirin for the commercialization of benralizumab for asthma and chronic obstructive pulmonary disease in Japan.
AGN: 317.00 (-0.75), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), AMAG: 72.59 (-1.83)
SAPHRIS® (asenapine) 2.5 mg Sublingual Tablets for the Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder in Pediatric Patients (ages 10-17) Now Available in Pharmacies throughout the U.S.
PR Newswire - Fri Jul 17, 7:00AM CDT
Allergan plc today announced that SAPHRIS® (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration (FDA) approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 - 17).
AGN: 317.00 (-0.75)
Which Top Biotechs Still In Play After Celgene Rally?
at Investor's Business Daily - Thu Jul 16, 5:45PM CDT
This week's list of leading stocks near buy points includes a healthy dose of medical names, from biotechs to managed care providers. The biotech revival began prior to Celgene's (CELG) 7% jump Wednesday on its $7.2 billion buy of Receptos (RCPT)....
MNK: 123.98 (+1.04), AGN: 317.00 (-0.75), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), UTHR: 175.17 (-2.34), RCPT: 228.98 (+0.26), MOH: 72.56 (-0.42), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01)
Allergan Faces Patent Challenge for Eye Treatment Restasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 1:35PM CDT
Allergan (AGN) is facing a patent challenge from Akorn for Restasis.
AGN: 317.00 (-0.75), EBIO: 2.95 (-0.04), MYL: 67.21 (+0.23), RDY: 60.75 (-1.31)
5 Big Stocks to Trade for Earnings Season Gains
at The Street - Thu Jul 16, 11:32AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street right now.
HRS: 81.29 (-0.26), BSX: 17.76 (-0.12), AGN: 317.00 (-0.75), HD: 113.86 (+0.45), HRL: 57.46 (-0.40)
The Antiepileptic Drug Topiramate Dominates First Line Prophylactic Treatment of Migraine, with Allergan's Botox Exhibiting Growth in Later Lines
PR Newswire - Thu Jul 16, 8:30AM CDT
Decision Resources Group finds that, through analysis of U.S. longitudinal patient-level claims data, the antiepileptic drug (AED) topiramate (Ortho-McNeil/Janssen-Cilag's Topamax; other brands; generics) captured the greatest patient share among prophylactic treatment-naive migraine patients across the first three lines of therapy. Furthermore, topiramate patient shares among migraine patients recently treated with prophylactic therapies remained relatively constant over the previous year of analysis. These findings highlight topiramate's position as a first-line standard of care for migraine prevention. Overall, AEDs were the preferred drug class for migraine prophylaxis, with nearly half of prophylactically naive patients initiating prophylactic therapy with an AED.
AGN: 317.00 (-0.75)
Top World Stocks In Bases Or Buy Range As Greece Votes
at Investor's Business Daily - Wed Jul 15, 4:50PM CDT
It's a good idea to scan through the charts of IBD's Top World Stocks. What you find right now is three of those stocks in bases and another two in buying range just above buy points. A resolution to the eurozone's crisis with Greece could quickly...
AGN: 317.00 (-0.75), MNK: 123.98 (+1.04), NTES: 151.05 (+0.88), SHPG: 255.23 (-2.57), ABBV: 70.54 (-0.26), FLTX: 49.64 (-0.24), ICLR: 68.17 (-0.70)
Allergan Notes Receipt of Paragraph IV Notification on Restasis
PR Newswire - Wed Jul 15, 3:01PM CDT
Allergan plc (NYSE: AGN) today confirmed that the Company has received a notice letter dated July 10, 2015 (the "Notice Letter"
from Akorn Pharmaceuticals stating that the U.S. Food and Drug Administration (FDA) has received Akorn's Abbreviated New Drug Application (ANDA) containing a "Paragraph IV" patent certification seeking approval to market a generic version of Allergan's Restasis® (cyclosporine ophthalmic emulsion) 0.05% product. In addition, Allergan has received communication suggesting that additional ANDAs for generic versions of Restasis® may have been received by the FDA. AGN: 317.00 (-0.75)
Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020
M2 - Wed Jul 15, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggwsk/global) has announced the addition of the "Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020" report to their offering. Alzheimer's disease is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer's disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. Global Alzheimer's Disease Drugs Market and Pipeline Drugs Analysis: In 2014, the global market for Alzheimer's disease drugs was dominated by Namenda and Exelon. Aricept and Memary stands at the third and fourth spot respectively in terms of Alzheimer's disease drugs sales in 2014. Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer's disease market. With the patent expiration of popular drugs the sales of the Alzheimer's drugs has also declined. However, there are several pipeline drugs like Solanezumab, Gantenerumab, Crenezumab and Lu AE58054 among others which are likely to hit the market during the period 2017 - 2020. Global Alzheimer's Disease Country Wise Analysis: In the Alzheimer's disease drugs market, the United States is the largest market. Japan is the second leading market for Alzheimer's disease drugs market in 2014. China stands at the third spot in the global Alzheimer's disease drugs market being followed by India. This report titled Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020 is a 150 page report with 74 Figures and 10 Tables. This report analyses the Alzheimer's Disease Drugs Market, Alzheimer's Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer's Disease - Country Wise Drugs Market, Country Wise Alzheimer's Disease Prevalence, Major Deals in Alzheimer's Disease Drugs Market Landscape, Funding in Alzheimer's Disease Drugs Research, Driving Factors and Challenges for Alzheimer's Disease Drugs Market. The Alzheimer's Disease Drugs Market has been analyzed from 7 View Points: 1. Alzheimer's Disease - Drugs Sales and Forecast 2. Alzheimer's Disease - Pipeline Drugs Sales Forecast 3. Alzheimer's Disease Drugs - Country Wise Market and Forecast 4. Alzheimer's Disease - Country Wise Prevalence and Forecast 5. Alzheimer's Disease - Pipeline Drugs Clinical Trials Analysis 6. Alzheimer's Disease - Major Deals in Alzheimer's Drugs Market 7. Alzheimer's Disease - Funding in Alzheimer's Disease Research The Top 9 Alzheimer's Disease Drugs covered in the report are as follows: 1. Exelon 2. Razadyne/Reminyl 3. Memary 4. Ebixa 5. Aricept 6. Rivastach 7. Namenda 8. Nootropil 9. Namzaric The 7 Pipeline Alzheimer's Disease Drugs covered in the report are as follows: 1. Solanezumab 2. ABT-126 3. idalopirdine 4. Gantenerumab 5. Crenezumab 6. Lu AE58054 7. BIIB037 The 9 Countries Alzheimer's Disease Drugs Market covered in the report are as follows: 1. United States 2. France 3. Germany 4. Italy 5. Spain 6. United Kingdom 7. Japan 8. China 9. India The Alzheimer's Disease Drugs Major Deals covered in the report are as follows: 1. Strategic Alliance 2. Licensing Agreement 3. Collaboration Deals 4. Mergers and Acquisitions Companies Mentioned - AbbVie - Allergan - Biogen - Daiichi Sankyo - Eisai - Lilly - Lundbeck - Novartis - Ono - Otsuka - Roche - Takeda For more information visit http://www.researchandmarkets.com/research/pggwsk/global
AGN: 317.00 (-0.75), NVS: 103.71 (-2.41)
'Mad Money' Lightning Round: I Still Believe in Harman International
at The Street - Wed Jul 15, 5:00AM CDT
Cramer thinks Walgreens, CVS and Rite Aid are great, prefers Allergan over Valeant and wants AT&T for growth and income.
AGN: 317.00 (-0.75), T: 34.57 (-0.33), VRX: 240.59 (+0.71), LC: 15.01 (+0.39), HAR: 109.25 (+3.21), WBA: 95.66 (+0.01), MPC: 57.15 (-0.38), CVS: 110.06 (-0.92), PYPLV: 38.39 (-0.24), RAD: 8.69 (-0.13)
